Hepatology

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	2667
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	2291
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	2060
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	1503
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	539
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	334
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	322
Late-Breaking Abstracts	316
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	281
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	242
Cover Image	237
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	204
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	200
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	199
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	186
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	173
Reply	159
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	150
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	145
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	142
Regulatory role and translational potential of CCL11 in liver fibrosis	142
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	133
Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC	132
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	129
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	127

Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?	124
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	122
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	122
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	118
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	118
Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma	117
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	115
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	113
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	106
Access to technology to support telehealth in areas without specialty care for liver disease	106
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	105
Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium	105
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	104
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	101
Efficacy and safety of infliximab in patients with autoimmune hepatitis	101
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	100
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	100
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	99
Genes that fit just right: Unzipping the genome of fatty liver disease	98
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	98
	98
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	97
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	97
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA	96
Letter to the Editor: Screening and risk stratification disparities in Hispanic MASLD	95
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	91
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	90
Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency	88
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	87
Erratum: Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells	85
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	85
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	84
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	84
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	79
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	79
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	78
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	77
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	76
Letter to the Editor: Overlooking the important factor: Hypoxia	76
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	75
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	75
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	75
Reply: Diabetes and fibrosis—Parallel risks or overlap?	74
Much more needed in natural history of Alagille syndrome	74
The international quest for the imaging diagnosis of liver cancer	74
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	72
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	69
In vivo imaging of calcium dynamics in zebrafish hepatocytes	69
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	69
Hepatocellular carcinoma with macrovascular invasion: Navigating heterogeneous evidence	68

Metabolic dysfunction-associated steatotic liver disease and the heart	68
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	68
NAFLD‐related hepatocellular carcinoma: The growing challenge	67
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	66
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	64
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	63
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	62
Reply: The CRAPT-M score: Robust enough for clinical practice?	62
Therapeutic manipulation of the microbiome in liver disease	61
The digital determinants of liver disease	61
Immunobiology of primary sclerosing cholangitis	60
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	60
Reply	60
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	58
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	58
Retraction: Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma	58
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	57
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	57
Reply: Deep learning and digital pathology power prediction of HCC development in steatotic liver disease	57
The clot and the complicated consult	56
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	56
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	56
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	56
A bright future: Sustainable treatment of gastric varices	55
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	54
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	54
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	54
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	54
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	52
Reply	52
Manuscript best practices: Takeaways from a community conversation	52
Reply	52
Reply	52
Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	52
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	52
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	52
Hepatology Highlights	51
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	51
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	51
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	51
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	50
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	49
Letter to the Editor: Placebo drift, dose heterogeneity, and the winner’s curse—Re-evaluating the hierarchy of MASH therapeutics	49
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	48
Integrative Hepatology: Enhancing overall health to manage liver disease	48
Pathway to global elimination of hepatitis B: HBV cure is just the first step	47
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	47
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	47
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	46
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation	46
Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study	46
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	46
AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation	45
Reply	45
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response	45
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	45
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	45
Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming	44
Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophages	44
Future directions in acute liver failure	44
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	43
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	43
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	43
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	43
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	43
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	43
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	42
Predicting liver outcomes with biomarker monitoring in MASLD	42
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	42
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	42
Masthead	42
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	42
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	42
Masthead	41
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	41
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	41
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	41
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	41
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	41
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	40

Letter to the Editor: The profile of HBsAg levels after nucleos(t)ide analogues treatment is crucial for achieving a functional cure	40
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	40
Letter to the editor: HuR in liver homeostasis	40
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	40
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	40
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	40
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	40
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	39
The Liver Meeting: 2025 Abstracts	39
Prognostic significance of mild ascites in patients with cirrhosis	39
Lipid nanoparticle-delivered ornithine transcarbamylase mRNA alleviates liver fibrosis in preclinical models	39
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	39
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	39
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	39
Intrahepatic cholangiocarcinoma PANoptosidy	38
Letter to the Editor: Key advance in noninvasive fibrosis assessment: Evidence from China	38
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	38
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	38
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	38
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	38
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	38
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	38
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	37
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	37
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	37
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	37
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	37
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	37
Anatomic subsets of cholangiocarcinoma: More different than alike	37
Stroma-driven inter- and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluation	37
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	37
Telehealth interventions in patients with chronic liver diseases: A systematic review	36
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	36
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	36
Letter to the Editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma	35
Erratum: Tertiary lymphoid structures in hepatocellular carcinoma: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	35
Erratum: Single-cell immune profiling of mouse liver aging reveals Cxcl2+ macrophages recruit neutrophils to aggravate liver injury	35
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	35
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	34
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	34
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	34
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	34
Imaging for better responses to immunotherapy in hepatocellular carcinoma	34
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab	34
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	34
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	34
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	33
A global action agenda for turning the tide on fatty liver disease	33
Category Index	33
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	33
Category Index	33
The evolving role of liver sinusoidal endothelial cells in liver health and disease	33
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening	32
Reply: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma	32
Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 axis in CTNNB1-mutant hepatocellular carcinoma	32
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	32
The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome	32
BileMet: A new frontier in distinguishing malignant from benign biliary conditions	32
Letter to the Editor: Assessing HCC risk in HBV indeterminate phase	32
LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism	31
Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding	31
Reply: More on nonalcoholic/nonmetabolic dysfunction–associated steatohepatitis	31
Deep learning’s crystal ball: Predicting HCC surgery success with multimodal imaging	31
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice	31
Retraction: Altered store operated calcium entry increases cyclic 3′,5′-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective	31
Erratum: IL-6–induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma	31
Population-level screening for liver disease: Opportunities and challenges	31
MASLD: To screen or not to screen—That is the question	31
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries	31
Letter to the Editor: Dynamic frailty trajectories and temporal measurement challenges in assessing liver transplantation survival benefit	31
Abdominal surgery in patients with chronic noncirrhotic extrahepatic portal vein obstruction: A multicenter retrospective study	30
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease	30
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi	30
Noninvasive liver disease assessment to identify portal hypertension: Systematic and narrative reviews supporting the AASLD Practice Guideline	30
Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor‐based combination therapies for hepatocellular carcinoma	30
AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension	30
New tricks for old molecules: A newly discovered modality for CAMs may yet lead to an HBV cure	30
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone	30
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma	30
Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B	30
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC	30
Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery	30
Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug‐induced liver injury	29
Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia	29
Hepatitis D virus—still the devil!	29
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series	29
Unmet needs in diagnosis and management of portopulmonary hypertension: How far have we reached?	29
Epigenetic heterogeneity hotspots in human liver disease progression	29
CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis	29
Targeting mTORC2-dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET–activated and β-catenin–mutated hepatocellular carcinoma	29
Benefit and harm of waiting time in liver transplantation for HCC	29
HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States	29
Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis	29
Will noninvasive screening for fibrosis/steatosis open Pandora’s box? Sharing the healthcare burden of state-of-the-art hepatology practice	28
Erratum: KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration	28